
|Videos|July 5, 2022
Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma
Author(s)Urology Times staff
“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.
Advertisement
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












